Vytorin and Electrocardiogram poor r-wave progression - a phase IV clinical study of FDA data

Summary:

Electrocardiogram poor r-wave progression is reported as a side effect among people who take Vytorin (ezetimibe; simvastatin), especially for people who are female, 50-59 old, also take Lasix, and have Diabetes.

The phase IV clinical study analyzes which people have Electrocardiogram poor r-wave progression when taking Vytorin. It is created by eHealthMe based on reports of 19,379 people who have side effects when taking Vytorin from the FDA, and is updated regularly.

What is Vytorin?

Vytorin has active ingredients of ezetimibe; simvastatin. It is often used in high blood cholesterol. eHealthMe is studying from 20,084 Vytorin users. Check the latest studies of Vytorin.

What is Electrocardiogram poor r-wave progression?

Electrocardiogram poor r-wave progression is found to be associated with 83 drugs and 249 conditions by eHealthMe. Check the latest studies of Electrocardiogram poor r-wave progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

19,379 people reported to have side effects when taking Vytorin.
Among them, 11 people (0.06%) have Electrocardiogram poor r-wave progression.

Could Vytorin cause Electrocardiogram poor r-wave progression?

Among these 11 people:

What is the gender of people who have Electrocardiogram poor r-wave progression when taking Vytorin? *

female: 63.64 %
male: 36.36 %

What is the age of people who have Electrocardiogram poor r-wave progression when taking Vytorin? *

What are other drugs people take besides Vytorin? *

What are other side effects people have besides Electrocardiogram poor r-wave progression? *

Chest Pain: 7 people, 63.64%
Cardiac Failure Congestive: 7 people, 63.64%
Nausea And Vomiting: 5 people, 45.45%
Dyspnea (difficult or laboured breathing): 5 people, 45.45%
Pain: 5 people, 45.45%
Nausea (feeling of having an urge to vomit): 5 people, 45.45%
Stress And Anxiety: 5 people, 45.45%
Multiple Injuries: 5 people, 45.45%
Diarrhea: 4 people, 36.36%
Fainting (loss of consciousness and postural tone): 4 people, 36.36%

What are the existing conditions these people have? *

Diabetes: 4 people, 36.36%
Stable Angina (a constant chest pain): 3 people, 27.27%
Cardiac Failure Congestive: 3 people, 27.27%
Balance Disorder: 3 people, 27.27%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 27.27%
Pain: 2 people, 18.18%
Hypersensitivity: 1 person, 9.09%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 9.09%
Depression: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Vytorin and have Electrocardiogram poor r-wave progression?

- Check whether Electrocardiogram poor r-wave progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vytorin:

Vytorin (20,084 reports)

Electrocardiogram poor r-wave progression treatments and more:

Electrocardiogram poor r-wave progression (339 reports)

How severe was Electrocardiogram poor r-wave progression and when was it recovered:

Electrocardiogram poor r-wave progression in Vytorin

Expand to all the drugs that have ingredients of ezetimibe; simvastatin:

Electrocardiogram poor r-wave progression and drugs with ingredients of ezetimibe; simvastatin (11 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vytorin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Electrocardiogram poor r-wave progression:

Electrocardiogram poor r-wave progression (83 drugs)

Browse all the conditions that are associated with Electrocardiogram poor r-wave progression:

Electrocardiogram poor r-wave progression (249 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ezetimibe; simvastatin (the active ingredients of Vytorin) and Vytorin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.